This clinical trial is focused on studying a condition called Geographic Atrophy, which is a form of Age-Related Macular Degeneration (AMD). AMD is an eye disease that can lead to vision loss in older adults. The treatment being tested in this study is called Pegcetacoplan, also known by its code name APL-2. Pegcetacoplan is administered as a solution for injection directly into the eye, a method known as intravitreal use.

The purpose of this study is to evaluate the long-term safety and effectiveness of Pegcetacoplan in individuals with Geographic Atrophy due to AMD. Participants in this study will receive regular injections of Pegcetacoplan over a period of time. The study will monitor the safety of the treatment and its impact on the progression of the disease. Participants will undergo various assessments to track changes in their vision and the condition of their eyes.

This study is an extension of previous research, meaning it continues to follow participants who have already been involved in earlier trials of Pegcetacoplan. The goal is to gather more information about how the treatment works over a longer period and to ensure it remains safe for use. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to collect valuable data on the treatment’s effects.